(A) KDM1A interacts with TCL1 and is increased in CLL. Higher levels are associated with more aggressive disease and shorter response to chemoimmunotherapy. (B) Knockdown of KDM1A in a mouse model alters gene expression, notably of genes regulating apoptosis and motility, alters methylation status, and works synergistically with agents, such as venetoclax, to increase CLL cell killing. BAK, BCL2 antagonist/killer 1; BAX, BCL2 associated X; BCL2, B-cell lymphoma 2; BIM, Bcl-2 interacting mediator of cell death. Professional illustration by Patrick Lane, ScEYEnce Studios.